Cartesian Therapeutics
NEWS
A safety concern has forced Takeda Pharmaceutical to suspend the dosing of patients in two Phase II studies of an experimental treatment for narcolepsy.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Selecta and Cyrus’ partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
Pharma and biotech companies from across the globe expand their leadership teams and boards.
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.
JOBS
IN THE PRESS